84. Sarcoidosis Clinical trials / Disease details
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01830959 (ClinicalTrials.gov) | April 2013 | 10/4/2013 | Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) | Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) | Sarcoidosis | Drug: Roflumilast;Drug: Placebo | University of Cincinnati | The Cleveland Clinic;University of Pittsburgh;University of Illinois at Chicago;Henry Ford Health System;Albany Medical College | Active, not recruiting | 18 Years | 70 Years | Both | 50 | Phase 4 | United States |